Seegene

Seegene OCF/Debt

The Operating Cash Flow to Debt Ratio of Seegene (096530.KQ) as of Nov 15, 2026 is 64,368.03 %. In the previous year, Operating Cash Flow to Debt Ratio was 11,184.37 % — a change of 475.52% (higher).

OCF/Debt

64,368.03 %

YoY

475.52%

Last updated:

Operating Cash Flow to Debt Ratio of Seegene is 2025 64,368.03 % . Operating Cash Flow to Debt Ratio of Seegene was 2024 11,184.37 % . It decreases by 475.52% higher compared to the previous year.

The Seegene OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2018
136.84 KRW
Jan 1, 2019
179.84 KRW
Jan 1, 2020
371.83 KRW
Jan 1, 2021
209.99 KRW
Jan 1, 2022
200.40 KRW
Jan 1, 2023
6,669.26 KRW
Jan 1, 2024
11,184.37 KRW
Jan 1, 2025
64,368.03 KRW
The Seegene OCF/Debt history
YEAROCF/DebtYoY
64,368.03 %+475.52%
11,184.37 %+67.70%
6,669.26 %+3,227.96%
200.40 %-4.57%
209.99 %-43.53%
371.83 %+106.76%
179.84 %+31.42%
136.84 %+167.82%
51.09 %+53.91%
33.20 %-595.20%
-6.70 %-130.36%
22.08 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Seegene Stock analysis

What does Seegene do? Seegene, Inc. generates revenue through the manufacturing and distribution of molecular diagnostics and reagents. The company offers infectious pathogens inspection products, including those for allergic respiratory pathogens, sexually transmitted diseases, and human papilloma virus (HPV), alongside drug resistance, single nucleotide polymorphisms (SNP), and somatic mutation cancer inspection products. It also provides automatic real-time detection instruments under the brand names Seeplex, Anyplex, and Magicplex. The firm serves both domestic and overseas markets with these products. The primary customers for Seegene's products are healthcare providers and laboratories requiring diagnostic solutions. The company's product portfolio targets specific medical needs such as infectious disease testing and cancer diagnostics. Its brands Seeplex, Anyplex, and Magicplex are used across various diagnostic applications, including respiratory and sexually transmitted disease testing. The firm's focus on molecular diagnostics positions it within the healthcare sector for specialized testing services. Seegene's revenue streams are derived from the sale of its branded diagnostic products and instruments. The company's domestic and overseas market distribution strategy supports its business model, with Seeplex, Anyplex, and Magicplex serving as key product lines. The firm's offerings cater to the growing demand for accurate and efficient molecular diagnostic solutions in healthcare settings. Seegene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Seegene stock

Operating Cash Flow to Debt Ratio of Seegene is 64,368.03 % in 2025.

Operating Cash Flow to Debt Ratio of Seegene changed from 11,184.37 % to 64,368.03 %, representing a 475.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Seegene since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Seegene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Seegene

All Key Metrics — Seegene